Directors

 

David G.P. Allan - Chairman

Mr. Allan incorporated the Canadian public company, YM BioSciences Inc, in 1994 and has been Chairman of the Board of Directors since incorporation and serving as Chief Executive Officer from 1998 through 2010. He has been the Executive Chairman of Stem Cell Therapeutics Corp., Canada's only public company developing stem cell therapeutics since July 2011. In addition, Mr. Allan is lead director of the public company, DiaMedica Inc. (diabetes therapeutics) in Canada and a number of private companies.

In the final decade of a 35-year career in investment banking he founded the first Canadian investment banking and research team specializing in the life sciences.

He is a former member of the Awards Selection Committee for the Networks of Centers of Excellence in Canada and Governor of The Toronto Stock Exchange. Mr. Allan is also a founding and sunset Chair of the Toronto Stock Exchange Market Access Implementation Committee that created access for small and medium-sized enterprises to Canada’s principal capital market and was a member, and working group Chair, of the Ontario Biotechnology Advisory Board. He has been a board member of the Shaw Festival Theatre and of the Board of Trustees for the Ontario College of Art and Design. Mr. Allan is currently a member of  BioteCanada’s Emerging Companies Advisory Board, and is a member of the board of directors of Life Sciences Ontario, both biotechnology industry organizations.


Joerg Gruber - Director

Mr. Gruber is an Investment Banker and Venture Capitalist with over 30 years of experience in international finance. He is a Founder and Chairman of Tarix Pharmaceuticals Limited and also a Founder and Chairman of Pathfinder Cell Therapy Inc., a public cell therapy company. He co-founded Clubb Capital Limited, a London-based corporate finance and venture capital firm with a focus on healthcare, in 1995 and has served as its Executive Chairman since 1999. Prior to his career in venture capital, Joerg spent 14 years in Banking and Investment Banking at UBS, Goldman Sachs and Lehman Brothers.


Andrew Maxwell - Director

Dr. Maxwell is the Chief Innovation Officer at the Canadian Innovation Centre and Assistant Professor, Strategy at Fox School of Business. Over the past 25 years, Dr. Maxwell has played a strategic role in the creation of new technology-based businesses and researching diagnostic factors that predict success or failure. He has co-founded early-stage technology companies and sits on the boards of a number of companies founded by former students he has taught at the Universities of Toronto and Waterloo. He is currently working on the FedDev-funded VentureStart program designed to increase the likelihood that nearly 200 technology ventures in Southern Ontario will succeed.



Niclas Stiernholm - Director

Dr. Stiernholm is the CEO of Trillium Therapeutics Inc. (TTI). He joined TTI from YM BioSciences, where he served as Executive Vice President and Chief Scientific Officer, playing a significant role in the success of its Initial Public Offering (IPO) in 2002. Dr. Stiernholm began his industry career as a member of Allelix Biopharmaceuticals' business development office and currently serves on several scientific and corporate boards of directors, including the Ontario Genomics Institute, AIM Therapeutics and Stem Cell Therapeutics Corp. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.



Ilia A. Tikhomirov - Director

Mr. Tikhomirov is the President and CEO of AvidBiologic Inc. Mr. Tikhomirov founded AvidBiologics in April 2011 as a spin-out from YM BioSciences, the Canadian biotechnology development company, where he had been involved in strategic research and business development from May 2007 to September 2010 and where he was latterly Associate Director of Science. While at YM he proposed, formulated and supported a hypothesis resulting from observations of an efficacious but largely non-toxic monoclonal antibody. These findings resulted in the foundational technology on which AvidBiologics is based. Mr. Tikhomirov is the co-inventor on a number of patents related to tumour-selective antibodies and antibody-drug conjugates, the focus of attention at AvidBiologics.

Board of Directors

DAVID G.P. ALLAN Chairman of AvidBiologics, Chairman of YM BioSciences, Chairman of Stem Cell Therapeutics

JOERG GRUBER Director of AvidBiologics, Chairman of Tarix Pharmaceuticals, Chairman of Pathfinder Cell Therapy

ANDREW MAXWELL Director of AvidBiologics, Chief Innovation Officer at the Canadian Innovation Centre

NICLAS STIERNHOLM Director of AvidBiologics, CEO of Trillium Therapeutics

ILIA A. TIKHOMIROV Director and CEO of AvidBiologics